BS01 Platform
Choroideremia
Key Facts
About Bionic Sight
Bionic Sight is a clinical-stage biotech pioneering a novel vision restoration platform that merges optogenetic gene therapy with neural code deciphering. Its lead program, BS01, is in Phase 1/2 trials for retinitis pigmentosa and geographic atrophy, with the RP program FDA Fast Tracked and preparing for Phase 3. Founded by MacArthur Award-winning neuroscientist Dr. Sheila Nirenberg, the company leverages world-class expertise in neural decoding and AAV gene therapy to address a significant unmet need in advanced blindness. Bionic Sight represents a unique, platform-based approach with potential applications across multiple retinal degenerative diseases.
View full company profileAbout Bionic Sight
Bionic Sight is a clinical-stage biotech pioneering a novel vision restoration platform that merges optogenetic gene therapy with neural code deciphering. Its lead program, BS01, is in Phase 1/2 trials for retinitis pigmentosa and geographic atrophy, with the RP program FDA Fast Tracked and preparing for Phase 3. Founded by MacArthur Award-winning neuroscientist Dr. Sheila Nirenberg, the company leverages world-class expertise in neural decoding and AAV gene therapy to address a significant unmet need in advanced blindness. Bionic Sight represents a unique, platform-based approach with potential applications across multiple retinal degenerative diseases.
View full company profileTherapeutic Areas
Other Choroideremia Drugs
| Drug | Company | Phase |
|---|---|---|
| KIO-301 | Kiora Pharmaceuticals | Preclinical |